SCHEMBL206755

SCHEMBL206755

O=C1Cc2ccccc2N1c1cc[c]cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.74
GAA P10253 5/20 0.47
TLR9 Q9NR96 2/20 0.47
PKM P14618 1/20 0.47
TNKS O95271 1/20 0.46
NOTUM Q6P988 1/20 0.44
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
CASP6 P55212 4/20 0.43
CASP3 P42574 2/20 0.43
SENP8 Q96LD8 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
SENP6 Q9GZR1 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
HTR7 P34969 5/20 0.40
HTR1A P08908 2/20 0.40
DRD2 P14416 1/20 0.40
DRD5 P21918 1/20 0.40
DRD3 P35462 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143970 0.85 HPGD (1.00) HPGDGAATLR9PKMTNKS
SCHEMBL31422646 0.85 HPGD (1.00) HPGDGAATLR9PKMTNKS
SCHEMBL6328308 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL27296976 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL4463146 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL16456324 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL6765903 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL6327688 0.79 HPGD (0.74) HPGDGAATLR9PKMTNKS
SCHEMBL367429 0.79 HPGD (0.68) HPGDGAATLR9PKMTNKS
SCHEMBL8539515 0.77 HPGD (0.83) HPGDGAATLR9PKMTNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2467144-A1 COMBINATION OF PROTEASOME INHIBITORS AND ANTI-HEPATITIS MEDICATION FOR TREATING HEPATITIS ViroLogik GmbH (DE) 2012-06-27 EP claimed
WO-2011009961-A1 COMBINATION OF PROTEASOME INHIBITORS AND ANTI-HEPATITIS MEDICATION FOR TREATING HEPATITIS VIROLOGIK GMBH (DE) 2011-01-27 WO claimed
US-20110020272-A1 COMBINATION THERAPY FOR TREATING HEPATITIS VIRAL INFECTION SCHUBERT ULRICH 2011-01-27 US claimed
US-20230149295-A1 INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO UNIVERSITY OF HOUSTON SYSTEM (US) 2023-05-18 US disclosed
EP-4121111-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS University of Houston System (US) 2023-01-25 EP disclosed
EP-4117718-A1 INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO University of Houston System (US) 2023-01-18 EP disclosed
US-20210401987-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS UNIVERSITY OF HOUSTON SYSTEM (US) 2021-12-30 US disclosed
WO-2021188849-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS UNIVERSITY OF HOUSTON SYSTEM (US) 2021-09-23 WO disclosed
WO-2021183474-A1 INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO UNIVERSITY OF HOUSTON SYSTEM (US) 2021-09-16 WO disclosed
US-8354440-B2 3-3-di-substituted-oxindoles as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-01-15 US disclosed
US-8268879-B2 3-3-di-substituted-oxindoles as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-09-18 US disclosed
US-7846962-B2 3-3-di-substituted-oxindoles as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-12-07 US disclosed
US-20100256388-A1 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-10-07 US disclosed
US-20100249201-A1 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-09-30 US disclosed
US-7737172-B2 3-3-di-substituted-oxindoles as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-06-15 US disclosed
US-20090299058-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-12-03 US disclosed
CN-101001842-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-07-18 CN disclosed
US-20070099976-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-05-03 US disclosed
EP-1718611-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION The President and Fellows of Harvard College (US) 2006-11-08 EP disclosed
WO-2005080335-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020272-A1 COMBINATION THERAPY FOR TREATING HEPATITIS VIRAL INFECTION HAVCR2, PSMA6, PSMB6 HPGD 1855/4885GAA 98/4885TLR9 841/4885
US-20100256388-A1 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation EIF2AK2, EIF5B, EIF4EBP1 HPGD 3029/4885GAA 3345/4885TLR9 3916/4885
US-20210401987-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS MMP1, MMP8, CCL11 HPGD 641/4885GAA 3641/4885TLR9 574/4885
US-20090299058-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION EIF2AK2, EIF5B, EIF4EBP1 HPGD 3029/4885GAA 3345/4885TLR9 3916/4885
US-20070099976-A1 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION EIF2AK2, EIF5B, EIF4EBP1 HPGD 3029/4885GAA 3345/4885TLR9 3916/4885
US-20230149295-A1 INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO EPCAM, FABP2, TPMT HPGD 1318/4885GAA 3567/4885TLR9 449/4885
US-20100249201-A1 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation EIF2AK2, EIF5B, EIF4EBP1 HPGD 3029/4885GAA 3345/4885TLR9 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.